Sedivet

Sedivet

Sedivet  Injection is used as a sedative and analgesic to facilitate handling, or during clinical examinations, clinical procedures, and minor surgical procedures in adult horses. the  Injection is also indicated as a preanesthetic prior to the induction of general anesthesia in adult horses. it contains romifidine hydrochloride. Sedivet 1% Injection is recommended for IV administration. Romifidine hydrochloride.

Boehringer Ingelheim Sedivet 1.0% Injection is indicated for use as a sedative and analgesic to facilitate handling, clinical examinations, clinical procedures, and minor surgical procedures in adult horses. Buy Sedivet 1.0% Injection is also indicated as a preanesthetic prior to the induction of general anesthesia in adult horses.

For more information or a special quotation, do not hesitate to contact us.

Sedative & Analgesic For Horses

(romifidine hydrochloride)

Boehringer Ingelheim Sedivet 1.0% Injection is indicated for use as a sedative and analgesic to facilitate handling, clinical examinations, clinical procedures, and minor surgical procedures in adult horses. Buy Sedivet 1.0% Injection is also indicated as a preanesthetic prior to the induction of general anesthesia in adult horses.

Dosage and Administration:

Sedation and Analgesia Dose: Administer slowly as a single IV injection using a dosage range of 40 – 120 µg/kg (0.4 – 1.2 ml/100 kg body weight) depending on the depth and duration of sedation that is required. The onset of action occurs in 30 seconds to 5 minutes, and gradually subsides during the next 2 to 4 hours. Degree of sedation and analgesia is dose-and time-dependent; therefore, more profound analgesia will occur with larger doses, as well as closer to the time of injection.

The horse should be allow to rest quietly for several minutes prior to and following injection.

The duration of analgesia is shorter than the duration of sedation.

Preanesthesia Dose:

A single IV injection using a dose of 100 µg/kg (1.0 mL/100 kg body weight) shows to be effective in the preanesthesia dose confirmation study. Anesthesia should be induce after maximum sedation is achieve. The administration of a2-agonists results in anesthetic sparing effects; therefore, anesthetic doses should be reduce to avoid overdose.

Mild to moderate sedation occurs within 2-4 minutes. Following induction, lateral recumbency occurs within 4 minutes, followed by complete anesthesia within 6-16 minutes. During recovery from anesthesia, sternal recumbency occurs within 12-83 minutes, followed by standing in 17-84 minutes. Recovery time is primarily determine by the choice of induction anesthetic and/or the duration of anesthesia.

Contraindications:

Intravenous potentiate sulfonamides should not be use in anesthetize or sedate horses as potentially fatal cardiac dysrhythmias may occur.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Not for human use. Keep this and all drugs out of the reach of children.

Not for horses intend for human consumption.

Although apparently deeply sedate, some horses may still respond to external stimuli with defensive movements (for example, kicking). Sedated horses are frequently ataxic. Routine safety measures should be use to protect practitioners and handlers.

Romifidine hydrochloride can be absorbe and may cause irritation following direct exposure to skin, eyes or mouth. In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminate clothing. In case of accidental oral exposure or injection, seek medical attention. If irritation or other adverse reaction occurs (for example, sedation, hypotension, bradycardia), seek medical attention.

As with all injectable drugs causing profound physiological effects. Precautions should be take by practitioners to prevent accidental self-injection when handling and using filled syringes. Users receiving treatment for blood pressure abnormalities should take special precaution to avoid exposure to this product.

Note to Veterinarian:

This product contains an a2-adrenoceptor agonist and can be absorbed by oral and dermal routes.

Precautions: The use of Buy Sedivet 1.0% Injection with other a2-agonists is not recommend since the effects (for example, cardiovascular changes, respiratory depression, ataxia) could be additive.

The use of epinephrine should be avoid since epinephrine may potentiate the effects of a2-agonists.

Anesthetic doses should be reduce in the presence of Sedivet 1.0% Injection to avoid excessive depression of the central nervous system.

Buy Sedivet 1.0% Injection has not been evaluate in horses with compromise cardiovascular function. The effects of bradycardia, increase vascular resistance, decrease cardiac output. And respiratory depression could be significant in horses with primary myocardial disease, or circulatory shock.

The Injection should not be use in horses with respiratory disease. Hepatic or renal disease, dehydration, or other systemic conditions of compromised health.

The effects of It 1.0% Injection have not been evaluate in horses with colic.

The effects of it 1.0% Injection have not been evaluate in pregnant mares. In horses intended for breeding, or in foals.

Adverse Reactions:

As with other drugs of this class, the administration of 1.0% Injection causes bradycardia (possibly profound). First and second degree atrioventricular heart block, and hypotension. The frequency and duration of cardiac arrhythmias have been show to be dose relate.

The following commonly occurring adverse reactions have been note using a2-agonists: hypertension. Hypotension, bradycardia, ataxia, piloerection, sweating, muscle tremors, salivation. Penile relaxation, urination (about an hour after treatment), lowering of head (causing passive congestion and swelling of face. Lips, upper airways), stridor, decrease gastrointestinal motility, flatulence, and mild colic.

The potential exists, as with all a2-agonists, for isolated incidences of excitation (paradoxical response).

Rare anaphylactic reactions have been reporte. Including one or more of the following: urticaria, dyspnea, edema of the upper airways and head, trembling, recumbency. And subsequent death.

Storage Information:

Store at control room temperature, 59-86°F (15-30°C).

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
error: Content is protected !!
Hello how can we help you?
Scan the code